Medindia LOGIN REGISTER
Medindia
Advertisement

Global Cell-Based Assays Market

Friday, October 24, 2014 Corporate News
Advertisement
NEW YORK, Oct. 23, 2014 /PRNewswire/ -- This report analyzes the worldwide markets for Cell-Based Assays in US$ Million by the following Applications: Basic Research, ADME Testing, and Drug Discovery. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 74 companies including many key and niche players such as - BD BiosciencesBeckman Coulter, Inc.BioVision, Inc.Cisbio BioassaysDiscoveRx Corporation
Advertisement

Read the full report: http://www.reportlinker.com/p0552745-summary/view-report.html

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3Basic Research I-3ADME Testing I-3Drug Discovery I-4II. EXECUTIVE SUMMARY1. INDUSTRY OVERVIEW II-1Cell-based Assays: A Most Promising Area in Cellular Biology II-1Table 1: Global Market for Cell-based Assays (2013):Percentage Share Breakdown of Value Sales by Segment(includes corresponding Graph/Chart) II-2Table 2: Global Market for Cell-based Assays (2013):Percentage Share Breakdown of Value Sales by End-User(includes corresponding Graph/Chart) II-2Developed Markets Dominate, While Asia-Pacific Lends GrowthMomentum II-2Major Trends, Growth Drivers and Restraints II-3Trends II-3Growth Drivers II-4Growth Restraints II-4Growing Prominence of Cell-based Assays in Drug Discovery II-4Cell-Based Assays Emerge as a Popular Tool in Basic Research II-6Use of Cell-based Assays in ADME-Toxicity Testing Gains Traction II-6Hepatotoxicity Testing Occupies Largest Market Share II-6Cell-based Assays in HTS and UHTS II-7Major Types of Cell-Based HTS Assays for Drug Screening II-8High-Content Screening (HCS) - A Rapidly Expanding ScreeningTechnology in Cell-Based Assays II-8High Content Screening - Key Application Areas II-9HCS vs. HTS II-9Outsourcing of Pharma R&D Gathers Momentum II-10Table 3: Worldwide Annual Spending on Drugs by Category (2011& 2015): Percentage Breakdown of Dollar Sales for BrandedDrugs, Generic Drugs, and Others (includes correspondingGraph/Chart) II-11Drug Discovery Outsourcing and Type of Services Outsourced II-11
Advertisement

2. MAJOR TRENDS & ISSUES II-12Growing Inclination towards In-vitro Assays for ToxicologyStudies II-12Time and Cost Benefits Drive Use of Cell-Based Assays overOther Techniques II-12Rising Number of Drug Targets Surge Demand for Cell-Based Assays II-12Growing Focus on the Development of Reproducible and RobustCell-based Assays II-13Stem Cells Exude Great Potential in Drug Toxicity Testing II-13Stem Cell Research in Cardiovascular Repair Rife with Hurdles II-14Increasing Use of Cell-Based Assays over Other Methods inToxicity Testing II-15Functional Assays: An Effective Way of Predicting SpecificToxic Effects II-15GPCR Targets to Drive Growth in Functional Cell Assay Market II-15Innovation in Screening Guarantees Success for Drug DiscoveryPrograms II-163D Cell Culture Technology to Put a New Spin on In Vitro CellAnalyses II-163D-CRT with Capability of Tracking Real Time 3D Position ofDiffusing Nanoparticles II-16Automated Multiplexing Platforms Present Growth Opportunities II-17Miniaturized Cell-based Assays on the Horizon II-17Rising Interest in Cell-based Assays Propels Development ofImproved Products II-17Automation of Cell-based Assays: A Growing Trend II-18Technology Advances in Drug Discovery Processes Spurs Cell-Based Assay Market II-18Development of Label-free Cell-based Assays: A Recent Trend inBiological Assays II-18Microfluidics Systems in Cell-based Assays II-19Cell-Based Assays Likely to Gain from Microfluidic Devices II-19Other Trends II-20Raman Spectroscopy: An Attractive Analytical Tool forPharmaceutical Industry II-20Fluorescence Spectroscopy for Cellular Imaging Analyses II-21Cell-based Immunoassays: Novel Assay Technology forAutoantibodies Detection II-21Shift Away from Established Cell Lines to Primary Cells II-22Role of Cell-based Assays in Personalized Medicine: A ResearchFocus II-22

3. CELL-BASED ASSAYS - APPLICATION AREAS II-23Cell-Based Assays in Drug Discovery II-23Table 4: Global Drug Discovery Market (2013): PercentageShare Breakdown of Revenues by Segment (includescorresponding Graph/Chart) II-23Drug Target Validation II-24Lead Identification II-24Lead Optimization II-24Sources and Types of Cells Available for Drug Screening II-24Cell-Based Assays in ADME Testing II-25Table 5: Leading Causes of Failure During New DrugDevelopment: Percentage Share Breakdown by ADME/Tox Issues,Insufficient Efficacy, Adverse Side Effects, and CommercialViability (includes corresponding Graph/Chart) II-26Need for Better Models: A Major Factor Driving Innovation inthe Market II-26

4. CELL-BASED ASSAYS: AN OVERVIEW II-28What Drives Advances in Cell-based Assays? II-28Cell Culture Fundamentals II-28An Insight into Cell Biology II-29Cell-based Assays: Basic Facts II-29Defining Cell-based Assays II-30Assays II-30Biological Assays II-30Quantification of Biological Activity II-30Cell-based Assays II-31Cell Based Assays: Prerequisites for Proof of Concept II-31List of Factors to be considered in Cell-Based Assays II-32Contamination with Mycoplasma: A Critical Factor II-32Modes of Contamination II-33Prevention II-33Uses of Cell-Based Assays II-33Challenges II-34Transient Transfection Cells II-34Limitations II-34Cell-based Assays: Product Segmentation II-34Assay Kits II-35Cell Function-Associated Assays II-35Cell Growth-Associated Assays II-35Select Methods of Evaluating Cell-Growth II-36Various Types of Cell Growth Associated Assays: II-36Cell Death-Associated Assays II-37Lab Automation II-38MIACA II-39

5. PRODUCT INTRODUCTIONS/INNOVATIONS II-40InSphero Releases 3D InSight™ Cytotoxicity Assay Kit II-40Clinigene Introduces Cell-Based Biomarker Assay II-40BioVision Launches EZViable™ Calcein AM Cell Viability AssayKit and MTS Cell Proliferation Assay Kit II-40Hepregen Rolls Out First Rat Hepatopactm Assay Kit forToxicology Applications II-40Labstract Launches Cell-Based Assay Services II-40Hepregen Unveils Human HepatoMune™ Assay Kit II-41Molecular Devices Launches EarlyTox™ Cell Integrity Kit II-41LGC Introduces cGMP Cell-based Assay Capability II-41SymCel Rolls Out Commercial Label-Free Cell-Based Assay II-41Platypus Technologies Introduces Oris™ Pro 96-Well Invasion Assay II-41BioVision Launches Cell-Based Cholesterol Efflux FluorometricAssay Kit II-41Promega Rolls Out GloMax® Discover Multimode Detection PlateReader System II-42Hepregen Launches First Monkey Hepatopac™ Assay Kits II-42DiscoveRx Launches New Human Primary Cell-Based T CellAutoimmune Panel II-42Hepregen Introduces Multi-Donor Human Hepatopac™ Assay II-42Hurel Introduces Cell-Based In Vitro Testing Product Suite II-42Thermo Fisher Scientific Releases Three New High ContentAnalysis Products II-42Thermo Fisher Scientific Launches Novel Incubation Solutionfor Cell-Based Research II-43DiscoveRx Introduces InCELL Hunter™ Platform II-43Cellectricon Launches Advanced Cell-Based Assay Systems II-43BioTek Launches Gas Controller for Synergy™ Hybrid Multi-ModeMicroplate Readers II-43Intertek Releases cGMP Cell-Based Assays II-43

6. RECENT INDUSTRY ACTIVITY II-44Promethera Biosciences Collaborates with EMD Millipore II-44Axxam and Cellectis Partner to Provide New Generation of Cell-Based Assays II-44TGR BioSciences and Abcam Enter into Licensing Agreement II-44Viradux Research Enters into JV Partnership with Benalli II-44Cellectricon Introduces Discovery Services Division II-44PPD Announces Expansion of cGMP Cell-based Assay Laboratory II-45Oxford Immunotec Enters into Licensing and PartnershipAgreements with Lophius Biosciences II-45Evotec Takes Over Cell Culture Service II-45GE Healthcare Inks Sublicense Agreement with Cellular Dynamicsfor Cellular Assay Patents II-45Discoverx Acquires BioSeek® II-45CEVEC and CSS Enter into License Agreement II-45Cyprotex Enters into Licensing Deal with Sigma® Life Science II-46Medicyte to Collaborate with Reinnervate to Develop 3D CellToxicity Assays II-46Affymetrix Acquires eBioscience Holding Company II-46SGS Inaugurates New Cell-Based Assay Laboratory II-46Corning Acquires Majority of BD's Discovery Labware Unit II-46

7. FOCUS ON SELECT GLOBAL PLAYERS II-47BD Biosciences (US) II-47Beckman Coulter, Inc. (US) II-47BioVision, Inc. (US) II-48Cisbio Bioassays (US) II-48DiscoveRx Corporation (US) II-49EMD Millipore Corp. (US) II-49Enzo Life Sciences, Inc. (US) II-50Evotec AG (Germany) II-51GE Healthcare Life Sciences (UK) II-51New England Biolabs, Inc. (US) II-52PerkinElmer, Inc. (US) II-52Promega Corporation (US) II-53ProQinase GmbH (Germany) II-54Qiagen NV (The Netherlands) II-54Sigma-Aldrich Corporation (US) II-55StemCells, Inc. (US) II-55Thermo Fisher Scientific, Inc. (US) II-56Life Technologies Corp. (US) II-56Xenometrix AG (Switzerland) II-57

8. GLOBAL MARKET PERSPECTIVE II-58Table 6: World Recent Past, Current and Future Analysis forCell-Based Assays by Geographic Region - US, Japan, Europe,and Rest of World Markets Independently Analyzed with AnnualSales Figures in US$ Million for Years 2013 through 2020(includes corresponding Graph/Chart) II-58Table 7: World Historic Review for Cell-Based Assays byGeographic Region - US, Japan, Europe, and Rest of WorldMarkets Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2006 through 2012 (includescorresponding Graph/Chart) II-59Table 8: World 15-Year Perspective for Cell-Based Assays byGeographic Region - Percentage Breakdown of Dollar Sales forUS, Japan, Europe, and Rest of World Markets for Years 2006,2014 and 2020 (includes corresponding Graph/Chart) II-60Cell-Based Assays Market by Application II-61Table 9: World Recent Past, Current and Future Analysis forCell-Based Assays for Basic Research by Geographic Region -US, Japan, Europe, and Rest of World Markets IndependentlyAnalyzed with Annual Sales Figures in US$ Million for Years2013 through 2020 (includes corresponding Graph/Chart) II-61

Table 10: World Historic Review for Cell-Based Assays forBasic Research by Geographic Region - US, Japan, Europe, andRest of World Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2006 through 2012 (includescorresponding Graph/Chart) II-62Table 11: World 15-Year Perspective for Cell-Based Assays forBasic Research by Geographic Region - Percentage Breakdown ofDollar Sales for US, Japan, Europe, and Rest of World Marketsfor Years 2006, 2014 and 2020 (includes correspondingGraph/Chart) II-63Table 12: World Recent Past, Current and Future Analysis forCell-Based Assays for ADME Testing by Geographic Region - US,Japan, Europe, and Rest of World Markets IndependentlyAnalyzed with Annual Sales Figures in US$ Million for Years2013 through 2020 (includes corresponding Graph/Chart) II-64

Table 13: World Historic Review for Cell-Based Assays for ADMETesting by Geographic Region - US, Japan, Europe, and Rest ofWorld Markets Independently Analyzed with Annual Sales Figuresin US$ Million for Years 2006 through 2012 (includescorresponding Graph/Chart) II-65Table 14: World 15-Year Perspective for Cell-Based Assays forADME Testing by Geographic Region - Percentage Breakdown ofDollar Sales for US, Japan, Europe, and Rest of World Marketsfor Years 2006, 2014 and 2020 (includes correspondingGraph/Chart) II-66Table 15: World Recent Past, Current and Future Analysis forCell-Based Assays for Drug Discovery by Geographic Region -US, Japan, Europe, and Rest of World Markets IndependentlyAnalyzed with Annual Sales Figures in US$ Million for Years2013 through 2020 (includes corresponding Graph/Chart) II-67Table 16: World Historic Review for Cell-Based Assays for DrugDiscovery by Geographic Region - US, Japan, Europe, and Restof World Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2006 through 2012 (includescorresponding Graph/Chart) II-68Table 17: World 15-Year Perspective for Cell-Based Assays forDrug Discovery by Geographic Region - Percentage Breakdown ofDollar Sales for US, Japan, Europe, and Rest of World Marketsfor Years 2006, 2014 and 2020 (includes correspondingGraph/Chart) II-69

III. MARKET1. THE UNITED STATES III-1A.Market Analysis III-1Cell-Based Assay Market to Witness Significant Growth III-1Functional Cell Assays - A Key Segment III-1Increased Usage Drives Growth of Cell-based Assays III-2Impact of Automation & High-Throughput Screening on CBA Market III-2Custom Designed Assays to Drive the US Cell-based Assay Market III-2Clinical Trials Market in the US III-3Competitive Scenario III-3Table 18: Leading Players in the US Cell-Based AssaysMarket (2013): Percentage Breakdown of Revenues forMillipore, Promega, EMD Biosciences, BD Biosciences, NewEngland Biolabs and Others (includes correspondingGraph/Chart) III-4Product Launches III-4Strategic Corporate Developments III-7Focus on Select Players III-8B.Market Analytics III-16Table 19: US Recent Past, Current and Future Analysis forCell-Based Assays by Application - Basic Research, ADMETesting and Drug Discovery Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2013through 2020 (includes corresponding Graph/Chart) III-16Table 20: US Historic Review for Cell-Based Assays byApplication - Basic Research, ADME Testing and DrugDiscovery Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2006 through 2012 (includescorresponding Graph/Chart) III-17Table 21: US 15-Year Perspective for Cell-Based Assays byApplication - Percentage Breakdown of Dollar Sales for BasicResearch, ADME Testing and Drug Discovery Markets for Years2006, 2014 and 2020 (includes corresponding Graph/Chart) III-18

2. JAPAN III-19Market Analysis III-19Table 22: Japanese Recent Past, Current and Future Analysisfor Cell-Based Assays by Application - Basic Research, ADMETesting and Drug Discovery Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2013through 2020 (includes corresponding Graph/Chart) III-19Table 23: Japanese Historic Review for Cell-Based Assays byApplication - Basic Research, ADME Testing and DrugDiscovery Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2006 through 2012 (includescorresponding Graph/Chart) III-20Table 24: Japanese 15-Year Perspective for Cell-Based Assaysby Application - Percentage Breakdown of Dollar Sales forBasic Research, ADME Testing and Drug Discovery Markets forYears 2006, 2014 and 2020 (includes correspondingGraph/Chart) III-21

3. EUROPE III-22A.Market Analysis III-22Current and Future Analysis III-22Pharmaceutical Companies Opt for Cell-Based Assays in DrugDiscovery III-22Rising Number of Drug Targets Surge Demand for Cell-BasedAssays III-22GPCR Targets to Drive Growth in Functional Cell Assay Market III-23Cell Growth-Based Assay Kits Market Makes Progress III-23Cell Death Based Assays: Efficiency Improvements inDevelopment Programs Favor Growth III-23Cell-based Assays Represent the Primary Drug Discovery Toolin HTS Laboratories III-24Advances in Technology, Identification Methods, and LabDisciplines in CBA Market III-24Regulatory Requirements in Cell-Based Assays Market III-24Validation Assays for Compliance with ICH Guidelines III-25Outsourcing of Validation Studies to CTOs III-25Growth of European Drug Discovery CRO Market: Opportunitiesfor CBA Market III-25Clinical Trials Market in Europe III-26Competitive Landscape III-26Product Launches III-27Strategic Corporate Developments III-28Focus on Select Players III-30B.Market Analytics III-33Table 25: European Recent Past, Current and Future Analysisfor Cell-Based Assays by Geographic Region - France,Germany, Italy, UK, Spain and Rest of Europe MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2013 through 2020 (includes correspondingGraph/Chart) III-33Table 26: European Historic Review for Cell-Based Assays byGeographic Region - France, Germany, Italy, UK, Spain andRest of Europe Markets Independently Analyzed with AnnualSales Figures in US$ Million for Years 2006 through 2012(includes corresponding Graph/Chart) III-34Table 27: European 15-Year Perspective for Cell-Based Assaysby Geographic Region - Percentage Breakdown of Dollar Salesfor France, Germany, Italy, UK, Spain and Rest of EuropeMarkets for Years 2006, 2014 and 2020 (includescorresponding Graph/Chart) III-35

Table 28: European Recent Past, Current and Future Analysisfor Cell-Based Assays by Application - Basic Research, ADMETesting and Drug Discovery Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2013through 2020 (includes corresponding Graph/Chart) III-36Table 29: European Historic Review for Cell-Based Assays byApplication - Basic Research, ADME Testing and DrugDiscovery Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2006 through 2012 (includescorresponding Graph/Chart) III-37Table 30: European 15-Year Perspective for Cell-Based Assaysby Application - Percentage Breakdown of Dollar Sales forBasic Research, ADME Testing and Drug Discovery Markets forYears 2006, 2014 and 2020 (includes correspondingGraph/Chart) III-38

4. REST OF WORLD III-39A.Market Analysis III-39Current and Future Analysis III-39Emerging Nations Capitalize on the Outsourcing Trend III-39China III-40Life Sciences Market in China Continues to Thrive DespiteRecession III-40China Emerges as the Major Outsourcer for Drug Discovery III-40China Begins Implementation of GLP Standard III-41Use of Non-Human Primates- A Key Feature of ChinesePharmaceutical Sector III-41Going Ahead III-41India III-42A Thriving Clinical Trials Market III-42Table 31: Cost of Conducting Clinical Trials: India Vs.US (In US$ Million) (includes corresponding Graph/Chart) III-43Strategic Corporate Developments III-43B.Market Analytics III-44Table 32: Rest of World Recent Past, Current and FutureAnalysis for Cell-Based Assays by Application - BasicResearch, ADME Testing and Drug Discovery MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2013 through 2020 (includes correspondingGraph/Chart) III-44Table 33: Rest of World Historic Review for Cell-BasedAssays by Application - Basic Research, ADME Testing andDrug Discovery Markets Independently Analyzed with AnnualSales Figures in US$ Million for Years 2006 through 2012(includes corresponding Graph/Chart) III-45Table 34: Rest of World 15-Year Perspective for Cell-BasedAssays by Application - Percentage Breakdown of Dollar Salesfor Basic Research, ADME Testing and Drug Discovery Marketsfor Years 2006, 2014 and 2020 (includes correspondingGraph/Chart) III-46

IV. COMPETITIVE LANDSCAPETotal Companies Profiled: 74 (including Divisions/Subsidiaries - 79)The United States (47)Japan (1)Europe (29)- France (3)- Germany (6)- The United Kingdom (10)- Italy (1)- Rest of Europe (9)Asia-Pacific (Excluding Japan) (2)

Read the full report: http://www.reportlinker.com/p0552745-summary/view-report.html

About Reportlinker ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com

__________________________Contact Clare: [email protected] US: (339)-368-6001Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cell-based-assays-market-245652452.html

SOURCE Reportlinker

Sponsored Post and Backlink Submission


Latest Press Release on Corporate News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close